Glaucoma Medications: Drug Classes, Mechanisms, and Side Effects for COA

Glaucoma pharmacology is one of the highest-yield topics on the COA exam within the Pharmacology and Glaucoma domains. The COA must understand not only which drugs are used but how they lower IOP, their dosing schedules, their side effects — local and systemic — and the clinical situations where one drug is preferred or contraindicated over another.

There are currently five classes of topical glaucoma medications: prostaglandin analogs, beta-adrenergic blockers, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors (CAIs), and rho kinase (ROCK) inhibitors. A sixth class — miotics like pilocarpine — was historically important but is now rarely used as first-line therapy. Understanding each class by mechanism, representative drugs, typical IOP reduction, dosing frequency, side effects, and contraindications forms the core of this topic.

The goal of all glaucoma therapy is to lower IOP sufficiently to halt progression of optic nerve damage and visual field loss. Each class achieves this through a different mechanism — either reducing aqueous humor production or increasing its outflow — and no single drug is ideal for all patients.

Five-Class Comparison Table

Class 1: Prostaglandin Analogs — First-Line Agents

Prostaglandin analogs are the most potent topical glaucoma agents available and are recommended as first-line monotherapy by most glaucoma guidelines. They reduce IOP by 25–35% by increasing uveoscleral (unconventional) outflow through the ciliary body and supraciliary space, bypassing the trabecular meshwork. Their once-nightly dosing (dosed at bedtime) is a major compliance advantage over agents requiring multiple daily doses.

Class 2: Beta-Adrenergic Blockers

Beta-blockers were the gold standard first-line agents before prostaglandins became available and remain widely used, especially in combination therapy. They reduce aqueous production by blocking beta-2 adrenergic receptors on the non-pigmented ciliary epithelium. Timolol (non-selective, blocking both beta-1 and beta-2) is the most commonly prescribed. Betaxolol (cardioselective, primarily beta-1) is preferred in patients with mild pulmonary disease as it has less bronchoconstrictor risk, though it is slightly less effective at lowering IOP.

Pulmonary Contraindication

Non-selective beta-blockers (timolol) are contraindicated in asthma, COPD, and reactive airway disease. Beta-2 blockade in bronchial smooth muscle causes bronchoconstriction. Even one drop of timolol can trigger life-threatening bronchospasm in susceptible patients. Always screen for respiratory history before prescribing.

Cardiac Contraindications

Beta-blockers are contraindicated in sinus bradycardia (heart rate below 60), second- or third-degree heart block, cardiogenic shock, and decompensated congestive heart failure. Beta-1 blockade (cardiac) slows heart rate and reduces contractility. Timolol eyedrops can reduce resting heart rate by 6–8 bpm with systemic absorption.

Masking of Hypoglycemia

Beta-blockers mask the tachycardia that signals hypoglycemia in diabetic patients on insulin. Alert prescribers when adding beta-blocker drops to insulin-dependent diabetics.

Short-Term Drift

Beta-blockers exhibit "short-term drift" — their IOP-lowering effect diminishes over the first few weeks of use as the ciliary body upregulates receptors. The long-term effect stabilizes at a lower level than initial response, which is why they are sometimes replaced by prostaglandins as first-line therapy.

Class 3: Alpha-2 Adrenergic Agonists

Brimonidine tartrate (Alphagan P) is the primary alpha-2 agonist in current use. It lowers IOP through two mechanisms: reducing aqueous production (by inhibiting adenylyl cyclase in ciliary epithelium) and increasing uveoscleral outflow. This dual mechanism makes it particularly effective as an additive agent. The Purite-preserved formulation (Alphagan P 0.1% and 0.15%) has a lower rate of local allergy than the original benzalkonium chloride formulations.

Apraclonidine (Iopidine 0.5%, 1%) is a less selective alpha-2 agonist used primarily as short-term adjunctive therapy before and after anterior segment laser procedures to blunt the post-laser IOP spike. It is not suitable for chronic use due to a very high rate of local allergic reactions (tachyphylaxis, follicular conjunctivitis).

Class 4: Carbonic Anhydrase Inhibitors (CAIs)

CAIs lower IOP by blocking carbonic anhydrase II in the non-pigmented ciliary epithelium, reducing bicarbonate secretion and thereby reducing aqueous humor production. Topical agents (dorzolamide 2% TID/BID, brinzolamide 1% TID) are used as additive therapy when prostaglandins or beta-blockers alone are insufficient.

Oral acetazolamide (Diamox) provides much more powerful IOP reduction (25–30%) and is used for acute angle-closure emergencies or when maximum IOP reduction is needed preoperatively. However, its systemic side effects (metabolic acidosis, hypokalemia, renal calculi, paresthesias, malaise, altered taste) limit long-term use.

Class 5: Rho Kinase (ROCK) Inhibitors

Netarsudil (Rhopressa 0.02%) is the first and only ROCK inhibitor approved for glaucoma. It works by a fundamentally different mechanism from all other classes: it increases conventional trabecular outflow — the primary physiological drainage route — by relaxing trabecular meshwork cells and increasing the permeability of Schlemm's canal. It also reduces episcleral venous pressure and aqueous production as secondary effects.

Netarsudil is dosed once nightly and approved as monotherapy or adjunct. It is also available in a fixed combination with latanoprost as Rocklatan, which provides additive IOP reduction from both the trabecular and uveoscleral outflow pathways.

Fixed Combination Drops

Fixed combination drops simplify regimens for patients on multiple agents, improving compliance by reducing the number of instillations per day. When two drops must be used separately, patients should wait at least 5 minutes between instillations to prevent the second drop from washing out the first.

Assessing Medication Compliance

Medication non-compliance is one of the leading causes of glaucoma progression despite adequate medical therapy. Research shows that a significant proportion of glaucoma patients (estimates range from 30–80%) are non-adherent to their prescribed regimens. The COA plays a critical role in assessing and supporting compliance through patient education.

Ask open-ended compliance questions

Rather than “Are you using your drops?” (which invites a yes answer), ask “How often do you miss a dose?” or “Walk me through how you use your drops each day.” This reveals actual habits without creating a defensive response.

Check for residual medication in bottles

Ask patients to bring their current bottles to appointments. Count remaining doses or note the fill date and refill date on the label. Bottles that should be nearly empty but are still mostly full indicate missed doses.

Reinforce the silent nature of glaucoma

Glaucoma causes no pain and vision loss is typically not noticed until late-stage disease. Patients may not feel motivated to treat a condition they cannot perceive. Explain that the drops protect the optic nerve from silent, irreversible damage and that vision loss cannot be reversed once it occurs.